Combination of potential biomarkers may help predict response to immunotherapy in kidney cancer
Currently, it is difficult for clinicians to decide which patients [...]
Summary from ASCO 2020 virtual meeting
This article nicely summarises the most exciting research highlights from [...]
Re-treatment with immune checkpoint inhibitors in kidney cancer patients
Immune checkpoint inhibitor combinations for the treatment of patients with [...]
Potential biomarker to predict outcomes in metastatic kidney cancer
A recent study published in Targeted Oncology last month investigates [...]
Potential biomarker for response to nivolumab for kidney cancer
Nivolumab was the first immunotherapy to be approved for the [...]
ASCO 2020: Subtypes of kidney cancer differ in sites of metastases
A paper presented during the 2020 American Society of Clinical [...]
Axitinib effective as a third-line treatment for kidney cancer
A recent study published in the journal In Vivo assessed [...]
Predictive factors for recurrence after complete metastasectomy in metastatic kidney cancer patients
In this retrospective study, published in Science Direct this month, [...]
First-line immunotherapy combination treatments for metastatic kidney cancer
A meta-analysis of four major clinical trials of immunotherapy combinations [...]
ASCO GU 2020: VEGF tyrosine kinase inhibitors as second-line treatment after immunotherapy for advanced kidney cancer
A retrospective analysis of data from the International Metastatic Renal [...]
